I70.29 I73.9
Conditions
Interventions
Group 1: Retrospective observation of patients who received LMWH (low molecular weight heparin) in a prophylactic dosage in addition to ASS and Clopidogrel for 4 weeks after blade-PTA (n = 100), 4 wee
Sponsors
LBT Zotz/Klimas
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Peripheral Artery Disease of the AFS or AP, treated by means of blade-PTA; observation period with inclusion of patients 2005 - 2011.
Exclusion criteria
Exclusion criteria: pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of re-PTA/stent or peripheral bypass surgery after index-PTA during the observation period of 5 years (2005-2011). | — |
Secondary
| Measure | Time frame |
|---|---|
| - decreased blood flow by ultrasonography - rate of clinical progression of the PAD (measured by means of decline of the painless walking distance or the Fontaine stage) - association of clinical (arterial hypertension, diabetes, hyperlipidemia, nicotine abuse, BMI, TASC score) and laboratory (fibrinogen, activators of protein C/S, antithrombin, factor VIII, factor V Leiden, prothrombin G20210A, platelet receptor polymorphisms (HPA-1a/b, GPIa807CT), homocysteine, cholesterol, triglycerides, lipoprotein (a)) variables with patency rate in vessels | — |
Countries
Germany
Contacts
Public ContactMichael Edelmann
LBT Zotz/Klimas
Outcome results
None listed